Drug Trial Radar · NCT06495944
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
Last checked: Nov 19, 2026Latest source record: Jul 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
21
Actual
Start
May 31, 2024
Primary completion
Aug 2, 2024
Study completion Aug 2, 2024
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 11, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study aims to answer how repeat doses of itraconazole impact the pharmacokinetics, safety, and tolerability of single doses of dazucorilant in healthy adults. Participants in this study will complete screening assessments within 28 days before the first dose of study drug. Those participants who can participate will be admitted to the clinical pharmacology center (CPC) and complete pretreatment tests. Those participants will stay at the CPC for the duration of the study. On Days 1 and 8, each participant will receive a single oral dose of dazucorilant 300 mg, after eating. On Days 5-11, all participants will receive once daily, oral doses of itraconazole 200 mg, after eating. Blood and safety assessments will continue for 96-hours after dosing on Day 1 and Day 8. Participants will leave the CPC following completion of all procedures on Day 12. Participants will return to the CPC for a final visit 7 (±1) days after their final dose of study medication.
Conditions
- Healthy Adults
Interventions
DazucorilantDrug
75 mg soft gelatin capsules formulation for oral administration
ItraconazoleDrug
100 mg capsules for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed plasma concentration (Cmax) of dazucorilantTime frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8
- Area under the concentration-time curve from time 0 to the last measurable concentration (AUClast) of plasma dazucorilantTime frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8
- Area under the concentration-time curve from time 0 extrapolated to infinity (AUCinf) of plasma dazucorilantTime frame: Predose and at serial timepoints up to 96 hours after dazucorilant dosing on Days 1 and 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site 01
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.